Thomas Decaens

13.2k total citations · 1 hit paper
141 papers, 3.9k citations indexed

About

Thomas Decaens is a scholar working on Hepatology, Epidemiology and Oncology. According to data from OpenAlex, Thomas Decaens has authored 141 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Hepatology, 48 papers in Epidemiology and 33 papers in Oncology. Recurrent topics in Thomas Decaens's work include Hepatocellular Carcinoma Treatment and Prognosis (76 papers), Liver Disease Diagnosis and Treatment (38 papers) and Cancer Immunotherapy and Biomarkers (18 papers). Thomas Decaens is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (76 papers), Liver Disease Diagnosis and Treatment (38 papers) and Cancer Immunotherapy and Biomarkers (18 papers). Thomas Decaens collaborates with scholars based in France, United States and South Korea. Thomas Decaens's co-authors include Zuzana Macek Jílková, Christine Perret, Sabine Colnot, Cécile Godard, Alexis Laurent, Christophe Duvoux, Matthias S. Matter, Jesper B. Andersen, Snorri S. Thorgeirsson and Gaël S. Roth and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Thomas Decaens

129 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.

2024 75 citations Peter R. Galle, Thomas Decaens et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Decaens France	31	2.3k	1.3k	1.1k	889	720	141	3.9k
Boheng Zhang China	33	2.2k 1.0×	1.6k 1.2×	982 0.9×	785 0.9×	1.1k 1.5×	83	4.1k
Gar‐Yang Chau Taiwan	27	1.7k 0.8×	1.2k 0.9×	973 0.8×	715 0.8×	539 0.7×	83	3.4k
Baogang Peng China	32	1.7k 0.8×	880 0.7×	1.0k 0.9×	810 0.9×	1.2k 1.7×	103	3.6k
Arndt Vogel Germany	8	2.5k 1.1×	1.3k 1.0×	730 0.6×	616 0.7×	831 1.2×	19	3.8k
Bang‐De Xiang China	30	2.1k 0.9×	1.3k 1.0×	529 0.5×	743 0.8×	842 1.2×	163	3.4k
Wen‐Ming Cong China	34	1.2k 0.5×	655 0.5×	1.4k 1.2×	718 0.8×	773 1.1×	135	3.4k
Gar-Yang Chau Taiwan	20	2.0k 0.9×	1.1k 0.9×	589 0.5×	491 0.6×	634 0.9×	37	2.9k
Tohru Utsunomiya Japan	37	1.3k 0.6×	880 0.7×	1.5k 1.3×	978 1.1×	1.7k 2.4×	166	4.3k
Sandra Rebouissou France	28	1.8k 0.8×	994 0.8×	2.5k 2.1×	1.2k 1.3×	1.0k 1.4×	40	5.0k

Countries citing papers authored by Thomas Decaens

Since Specialization

Citations

This map shows the geographic impact of Thomas Decaens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Decaens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Decaens more than expected).

Fields of papers citing papers by Thomas Decaens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Decaens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Decaens. The network helps show where Thomas Decaens may publish in the future.

Co-authorship network of co-authors of Thomas Decaens

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Decaens. A scholar is included among the top collaborators of Thomas Decaens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Decaens. Thomas Decaens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Allaire, Manon, Julien Edeline, P. Merle, et al.. (2025). 1487P Extended follow-up at 42 months of atezolizumab–bevacizumab in advanced HCC: Insights from the CHIEF prospective study. Annals of Oncology. 36. S829–S829.

Chuffart, Florent, Thomas Decaens, Marie‐Noëlle Hilleret, et al.. (2025). HBV and HBsAg strongly reshape the phenotype, function, and metabolism of DCs according to patients’ clinical stage. Hepatology Communications. 9(2). 2 indexed citations

Decaens, Thomas, Joseph P. Erinjeri, Riccardo Lencioni, et al.. (2024). 166P Outcomes by baseline liver function in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) with or without bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC). Annals of Oncology. 35. S74–S75.

Tron, Laure, Agnieszka Borowik, Anne‐Laure Borel, et al.. (2024). Early screening for chronic liver disease: impact of a FIB-4 first integrated care pathway to identify patients with significant fibrosis. Scientific Reports. 14(1). 20720–20720.

Viallet, Jean, et al.. (2024). Liver cancer in ovo models for preclinical testing. The FASEB Journal. 38(17). e70029–e70029.

Kudo, Masatoshi, Ann‐Lii Cheng, Philippe Merle, et al.. (2024). Association between beta-catenin (CTNNB1) mutations and clinical outcomes of pembrolizumab in advanced hepatocellular carcinoma (aHCC): Exploratory analyses from KEYNOTE-240.. Journal of Clinical Oncology. 42(16_suppl). 4109–4109. 1 indexed citations

Galle, Peter R., Thomas Decaens, Masatoshi Kudo, et al.. (2024). Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.. Journal of Clinical Oncology. 42(17_suppl). LBA4008–LBA4008. 75 indexed citations breakdown →

El-Khoueiry, Anthony B., Tae‐You Kim, Jean‐Frédéric Blanc, et al.. (2024). International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology. 42(16_suppl). 4007–4007. 13 indexed citations

Lim, Ho Yeong, Jeong Heo, Baek‐Yeol Ryoo, et al.. (2024). Efficacy and safety of bintrafusp alfa in 2 phase I expansion cohorts with advanced HCC. Hepatology. 81(1). 32–43. 4 indexed citations

10.

Harding, James J., Ahmad Awada, Gaël S. Roth, et al.. (2022). First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers. Liver Cancer. 11(3). 268–277. 16 indexed citations

11.

Roth, Gaël S., Olivier Hernandez, Julien Ghelfi, et al.. (2022). Safety and Efficacy of Transarterial Chemoembolization in Elderly Patients with Intermediate Hepatocellular Carcinoma. Cancers. 14(7). 1634–1634. 3 indexed citations

12.

Kurma, Keerthi, Julien Ghelfi, Carole Fournier, et al.. (2022). Chronic Intermittent Hypoxia Increases Cell Proliferation in Hepatocellular Carcinoma. Cells. 11(13). 2051–2051. 8 indexed citations

13.

Dorival, Céline, Carole Cagnot, Hélène Fontaine, et al.. (2022). Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response. Clinics and Research in Hepatology and Gastroenterology. 46(6). 101923–101923. 14 indexed citations

14.

Roth, Gaël S., et al.. (2021). Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment. International Journal of Molecular Sciences. 22(4). 1794–1794. 36 indexed citations

15.

Marche, Patrice N., et al.. (2019). APPLICATION OF ALPHA-FETOPROTEIN AND OSTEOPONTIN COMBINATION FOR EARLY DIAGNOSIS OF HEPATOCELLULAR CARCINOMA ASSOCIATED WITH HEPATITIS C. Russian Clinical Laboratory Diagnostics. 64(10). 607–612. 1 indexed citations

16.

Roth, Gaël S., Zuzana Macek Jílková, Keerthi Kurma, et al.. (2017). Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma. Molecular Cancer Therapeutics. 16(10). 2157–2165. 23 indexed citations

17.

Jílková, Zuzana Macek, Samia Afzal, Thomas Decaens, et al.. (2016). Progression of fibrosis in patients with chronic viral hepatitis is associated with IL ‐17 ⁺ neutrophils. Liver International. 36(8). 1116–1124. 34 indexed citations

18.

Caldéraro, Julien, Jean‐Charles Nault, Paulette Bioulac‐Sage, et al.. (2013). ALDH3A1 is overexpressed in a subset of hepatocellular carcinoma characterised by activation of the Wnt/ß-catenin pathway. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 464(1). 53–60. 23 indexed citations

19.

Baranès, Laurence, Thomas Decaens, Daniel Cherqui, et al.. (2012). Recurring multicystic inflammatory pseudotumor of the liver: A case report. Clinics and Research in Hepatology and Gastroenterology. 37(2). e51–e57. 3 indexed citations

20.

Colnot, Sabine, Thomas Decaens, & Christine Perret. (2005). Activer un signal β-caténine dans le foie est oncogénique. médecine/sciences. 21(4). 355–357. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact